Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
Clinical trial NCT05948462 · WITHDRAWN
Trial details
- NCT number
- NCT05948462
- Sponsor
- SCRI Development Innovations, LLC
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-01
- Primary completion
- 2025-03-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.